Stoke Therapeutics, Inc.

NASDAQ:STOK

13.27 (USD) • At close November 7, 2024
Bedrijfsnaam Stoke Therapeutics, Inc.
Symbool STOK
Munteenheid USD
Prijs 13.27
Beurswaarde 698,636,306
Dividendpercentage 0%
52-weken bereik 3.77 - 17.58
Industrie Biotechnology
Sector Healthcare
CEO Dr. Edward M. Kaye M.D., Ph.D.
Website https://www.stoketherapeutics.com

An error occurred while fetching data.

Over Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is

Vergelijkbare Aandelen

Geron Corporation logo

Geron Corporation

GERN

4.29 USD

PetIQ, Inc. logo

PetIQ, Inc.

PETQ

30.98 USD

Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc.

TNGX

2.83 USD

GH Research PLC logo

GH Research PLC

GHRS

8.62 USD

Aura Biosciences, Inc. logo

Aura Biosciences, Inc.

AURA

10.96 USD

Computer Programs and Systems, Inc. logo

Computer Programs and Systems, Inc.

CPSI

9.19 USD

Century Therapeutics, Inc. logo

Century Therapeutics, Inc.

IPSC

1.46 USD

SI-BONE, Inc. logo

SI-BONE, Inc.

SIBN

15.57 USD

Y-mAbs Therapeutics, Inc. logo

Y-mAbs Therapeutics, Inc.

YMAB

15.55 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)